Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-a-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsAchieved first-in-human combination dosing of a PD-1 inhibitor with one of our potential new medicines, with recent dosing of VMT01 in combination with nivolumabIND cleared for PSV359, which targets FAP-a, associated with multiple highly prevalent solid tumors, with p
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- Perspective Therapeutics, Inc. (NYSE: CATX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Perspective Therapeutics to Participate in Upcoming April Investor ConferencesGlobeNewswire
- Perspective Therapeutics, Inc. (NYSE: CATX) had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.MarketBeat
- Perspective Therapeutics, Inc. (NYSE: CATX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
CATX
Earnings
- 11/12/24 - In-Line
CATX
Sec Filings
- 4/1/25 - Form 4
- 4/1/25 - Form 4
- 4/1/25 - Form 4
- CATX's page on the SEC website